Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (871-880 of 903) with videos related to

Pageof 91
Sort By:
JCI Insight|April 22, 2024
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemiaOla A Elgamal, Sydney Fobare, Sandip Vibhute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AMLJoshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Leukemia|June 15, 2026
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemiaDarren Lee, Yazan Abu-Shihab, Kate Plas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2012
Non-Hodgkin's Lymphomas, version 3.2012Andrew D Zelenetz, William G Wierda, Jeremy S Abramson, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Haematologica|October 10, 2024
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapyFederico Mosna, Erika Borlenghi, Mark Litzow, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Prognostic and Therapeutic Implications of <i>BRAF</i> Mutations in Acute Myeloid LeukemiaDarren Lee, Yazan Abu-Shihab, Kate Plas, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2013
Non-Hodgkin's lymphomas, version 1.2013Andrew D Zelenetz, William G Wierda, Jeremy S Abramson, et al.
Pageof 91

Showing results (871-880 of 903) with videos related to

Sort By:
Pageof 91
JCI Insight|April 22, 2024
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemiaOla A Elgamal, Sydney Fobare, Sandip Vibhute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AMLJoshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Leukemia|June 15, 2026
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemiaDarren Lee, Yazan Abu-Shihab, Kate Plas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2012
Non-Hodgkin's Lymphomas, version 3.2012Andrew D Zelenetz, William G Wierda, Jeremy S Abramson, et al.
The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.
Haematologica|October 10, 2024
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapyFederico Mosna, Erika Borlenghi, Mark Litzow, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Prognostic and Therapeutic Implications of <i>BRAF</i> Mutations in Acute Myeloid LeukemiaDarren Lee, Yazan Abu-Shihab, Kate Plas, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2013
Non-Hodgkin's lymphomas, version 1.2013Andrew D Zelenetz, William G Wierda, Jeremy S Abramson, et al.
Pageof 91